Detection of prostate cancer with three-dimensional transrectal ultrasound: correlation with biopsy results

被引:14
作者
Zhao, H-X [2 ]
Zhu, Q. [2 ]
Wang, Z-C [1 ]
机构
[1] Capital Med Univ, Dept Radiol, Beijing Tongren Hosp, Beijing 100730, Peoples R China
[2] Capital Med Univ, Dept Diagnost Ultrasound, Beijing Tongren Hosp, Beijing 100730, Peoples R China
关键词
POWER DOPPLER; GRAY-SCALE; SONOGRAPHY; COLOR; CARCINOMA; DIAGNOSIS; MEN; US;
D O I
10.1259/bjr/68418881
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives: The aim of this study was to evaluate the role of three-dimensional transrectal ultrasound in the diagnosis of prostate cancer. Methods: A total of 112 patients with elevated serum prostate-specific antigen (PSA) or a positive digital rectal examination were evaluated using three-dimensional greyscale transrectal ultrasound (3D-GS TRUS) and three-dimensional power Doppler sonography (3D-PDS). Target biopsies were obtained together with 12 core systematic biopsies. Pathological results were correlated with the imaging data. Results: Cancers were detected in 269 biopsy sites from 41 patients. 229 sites of cancer were depicted by 3D-GS TRUS and 213 sites were depicted by 3D-PDS. 30 sites were missed by both 3D-GS TRUS and 3D-PDS. Abnormal prostate images depicted by 3D-GS TRUS and 3D-PDS were associated with lesions with a Gleason score of 6.9 or higher. Conclusion: The detection rates of prostate cancer were significantly improved with 3D-GS TRUS and 3D-PDS on serum PSA levels >10 ng ml(-1) or 20ng ml(-1). 3D-GS TRUS and 3D-PDS may improve the biopsy yield by determining appropriate sites for target and systematic biopsies. The abnormalities detected by 3D ultrasound were associated with moderate-and high-grade prostate cancers. However, based on the number of false-negative TRUS results, the use of systematic prostate biopsies should not be eliminated.
引用
收藏
页码:714 / 719
页数:6
相关论文
共 21 条
[1]   LONG-TERM SURVIVAL AMONG MEN WITH CONSERVATIVELY TREATED LOCALIZED PROSTATE-CANCER [J].
ALBERTSEN, PC ;
FRYBACK, DG ;
STORER, BE ;
KOLON, TF ;
FINE, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (08) :626-631
[2]  
BYAR DP, 1972, CANCER-AM CANCER SOC, V30, P5, DOI 10.1002/1097-0142(197207)30:1<5::AID-CNCR2820300103>3.0.CO
[3]  
2-S
[4]   PATHOLOGICAL AND CLINICAL FINDINGS TO PREDICT TUMOR EXTENT OF NONPALPABLE (STAGE-T1C) PROSTATE-CANCER [J].
EPSTEIN, JI ;
WALSH, PC ;
CARMICHAEL, M ;
BRENDLER, CB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (05) :368-374
[5]   Using gray-scale and color and power Doppler sonography to detect prostatic cancer [J].
Halpern, EJ ;
Strup, SE .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2000, 174 (03) :623-627
[6]   Three-dimensional US of the prostate: Early experience [J].
Hamper, UM ;
Trapanotto, V ;
DeJong, MR ;
Sheth, S ;
Caskey, CI .
RADIOLOGY, 1999, 212 (03) :719-723
[7]   Predictors of prostate carcinoma: Accuracy of gray-scale and color Doppler US and serum markers [J].
Kuligowska, E ;
Barish, MA ;
Fenlon, HM ;
Blake, M .
RADIOLOGY, 2001, 220 (03) :757-764
[8]   Prostatic cancer: Role of color Doppler imaging in transrectal sonography [J].
Lavoipierre, AM ;
Snow, RM ;
Frydenberg, M ;
Gunter, D ;
Reisner, G ;
Royce, PL ;
Lavoipierre, GJ .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1998, 171 (01) :205-210
[9]  
MCNEAL JE, 1969, CANCER, V23, P24, DOI 10.1002/1097-0142(196901)23:1<24::AID-CNCR2820230103>3.0.CO
[10]  
2-1